Holland High Tech Holland High Tech
PRISM

Personalized Rx through Intelligent and Scalable Manufacturing

PRISM develops an automated platform for the production of personalized medicines in hospital and compounding pharmacies. The project combines pharmaceutical 3D printing, standardized formulations, intelligent software and scalable manufacturing technology to reduce pharmacy workload, improve access to personalized medicines and contribute to more affordable and accessible healthcare.

The challenge of personalized medicines

An increasing number of patients require medicines tailored to their individual needs. Examples include children, elderly patients and individuals requiring non-standard doses, combinations of medicines or specific dosage forms. Today, such medicines are often produced through manual manipulation of commercial products or small-scale compounding activities. These processes are labor-intensive, difficult to scale and place a substantial burden on pharmacies. At the same time, healthcare systems face rising costs and growing shortages of qualified healthcare personnel.

A new generation of pharmaceutical manufacturing technology

PRISM develops an integrated platform for automated production of personalized medicines. The platform combines a scalable pharmaceutical 3D printer, flexible cartridge concepts, standardized formulation platforms and advanced software tools. This enables medicines to be produced more efficiently, consistently and with less manual handling. In addition, decision-support software will be developed that recommends suitable formulation platforms based on the properties of an active pharmaceutical ingredient, helping to accelerate implementation and reduce development effort.

Impact on healthcare and Dutch innovation

PRISM supports the transition from labor-intensive medicine preparation to digitally enabled manufacturing of personalized medicines. This can improve pharmacy efficiency, increase the availability of personalized treatments and help healthcare systems address future workforce shortages. In addition, the project strengthens the Dutch position in pharmaceutical 3D printing and personalized medicine manufacturing. The resulting knowledge, intellectual property and technological developments will create opportunities for new products, services and economic activity within the Dutch MedTech and high-tech sectors.

Facts & figures
  • Scheme: PPS-I Strategische Programma's
  • Programme: Medische Technologie | 2024-2027
  • Total budgeted project costs: € 890.100,00
  • Project start date: 1 January 2027
  • Project end date: 31 December 2028
Project managers
Project consortium
TNO Duchefa Farma Stichting C busineZ Erasmus MC Doser Simac Masic Leids Universitair Medisch Centrum (LUMC) Digitalis Mx
Sign up for our newsletter